Biotech News

Charles River Laboratories Announces Second-Quarter 2026 Results

Charles River (CRL)Charles River2026-08-05 11:00 ESTEarnings

WILMINGTON, Mass. --(BUSINESS WIRE)--Aug. 5, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter ended June 27, 2026. Key Highlights Reports second-quarter revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings

Related news

CRLCharles River2026-07-15 12:00 EST

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

CRLCharles River2026-05-07 11:00 EST

Charles River Laboratories Announces First-Quarter 2026 Results

View all latest news

Charles River

Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and...

Recent company news

CRLCharles River2026-08-05 11:00 EST

Charles River Laboratories Announces Second-Quarter 2026 Results

CRLCharles River2026-07-15 12:00 EST

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

CRLCharles River2026-07-13 12:00 EST

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

CRLCharles River2026-06-18 12:00 EST

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

CRLCharles River2026-06-01 12:00 EST

Charles River Laboratories to Present at William Blair and Jefferies Conferences

Stock data

Close: 265.51 USD
Market cap: 8.42B USD
Exchange: NYSE
Sector: Biopharma
Location: United States